摘要
随着肿瘤免疫学理论和技术的发展,恶性血液肿瘤的治疗迎来新的纪元,过继性细胞免疫治疗(ACI)已成为研究热点.其中,利用嵌合抗原受体(CAR)修饰的T细胞治疗恶性血液肿瘤,在各项试验中均获得显著疗效.笔者拟就CAR-T细胞的构建及靶点选择,近年来与CAR-T细胞治疗相关的体内、外试验和临床研究,以及CAR-T细胞治疗目前尚待解决的问题进行综述.
With the development of tumor immunological theory and technology,the treatment of blood malignancies is in a new era.Adoptive cellular immunotherapy (ACI) has become the hotspot of researches.Chimeric antigen receptor (CAR) modified T cell shows prominent therapeutic effect in various trails treating blood malignancies.In this paper,we describe the construction of CAR-T cell,choice of targets,clinical experiments related to CAR-T cell therapy in recent years,and the problems remain to be solved.
出处
《国际输血及血液学杂志》
CAS
2015年第1期69-72,共4页
International Journal of Blood Transfusion and Hematology
基金
广东省临床重点专科基金资助项目,Project No.20111219
关键词
抗原受体
血液肿瘤
细胞免疫治疗
过继
Receptors,antigen
Hematologic neoplasms
Cellular immunotherapy,adoptive